Pharming (PHAR) Depreciation & Amortization (CF) (2020 - 2026)

Pharming (PHAR) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $11.2 million in Q4 2025.

• Quarterly Depreciation & Amortization (CF) fell 30.21% year-over-year to $11.2 million in Q4 2025, while the trailing twelve-month figure through Jun 2026 was $11.2 million (down 40.38% YoY) and the FY2025 annual result came in at $11.2 million, changed N/A from the prior year.
• Depreciation & Amortization (CF) eased to $11.2 million in Q4 2025, from $16.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $16.1 million in Q4 2024 to a low of -$4.4 million in Q3 2021.
• A 5-year average of $4.7 million and a median of $2.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 23680.7% in 2021, down 291.63% in 2021.
• Tracing PHAR's Depreciation & Amortization (CF) over 5 years: stood at $2.1 million in 2021, then rose by 6.16% to $2.2 million in 2022, then soared by 244.98% to $7.6 million in 2023, then surged by 112.71% to $16.1 million in 2024, then slumped by 30.21% to $11.2 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $11.2 million (Q4 2025), $16.1 million (Q4 2024), and $2.7 million (Q3 2024), per Business Quant data.